Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies

Clinical trial NCT05240690 · UNKNOWN

Trial details

NCT number: NCT05240690
Sponsor: Zhou Fuxiang
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Stage IV Pancreatic Cancer Hepatocellular Carcinoma , Cholangiocarcinoma

Start date: 2022-02-07
Primary completion: 2023-12-31
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.